CTMX Q1 2022 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-43.4% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$32M-354.7% margin

Net Income

-$32M-353.8% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

-54.2%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$42M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$297M

Total Liabilities

$229M

Stockholders' Equity

$68M

Cash & Equivalents

$163M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$16M	-43.4%
Gross Profit	$9M	$16M	-43.4%
Operating Income	-$32M	-$16M	-105.2%
Net Income	-$32M	-$16M	-105.6%